Valiant Laboratories Publishes Audited Financial Results for FY26
Valiant Laboratories published its audited financial results for the quarter and year ended March 31, 2026. Total income for the year was ₹5,842.39 crore, with a net profit of ₹363.28 crore. For the quarter, income was ₹2,199.37 crore and net profit was ₹323.83 crore. Basic EPS for the year was ₹0.74.
Publication of financial results is material information for investors and impacts their investment decisions. The specific figures within the results will determine the actual market impact.
The announcement is a routine publication of financial results, which is a standard disclosure. While the results themselves might have positive or negative implications, the act of publication is neutral.
Valiant Laboratories Limited has announced the publication of its audited financial results for the quarter and year ended March 31, 2026. The results were published in the Financial Express (English) and Mumbai Lakshadeep (Marathi) newspapers on May 16, 2026.
These results include both standalone and consolidated financial statements. The company has also uploaded this intimation on its official website, www.valiantlabs.in, for public access.
The published financial statement indicates a total income of ₹5,842.39 crore for the year ended March 31, 2026, compared to ₹9,215.30 crore in the previous year. The net profit after tax for the year stood at ₹363.28 crore, a decrease from ₹215.02 crore in the prior year. For the quarter ended March 31, 2026, the total income was ₹2,199.37 crore, and the net profit after tax was ₹323.83 crore.
The company's paid-up equity share capital as of March 31, 2026, was ₹541.25 lakh. Earnings per share (basic) for the year ended March 31, 2026, were ₹0.74, down from ₹0.35 in the previous year. For the quarter, basic EPS was ₹0.14.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.